Secondary malignant neoplasms after high‐dose chemotherapy and autologous stem cell rescue for high‐risk neuroblastoma
Pediatric Blood & Cancer2014Vol. 61(8), pp. 1350–1356
Citations Over TimeTop 10% of 2014 papers
Alissa Martin, Jennifer Schneiderman, Irene Helenowski, Elaine Morgan, Kimberley Dilley, Karina Danner‐Koptik, Mohamad Hatahet, Hiroyuki Shimada, Susan L. Cohn, Morris Kletzel, Nobuko Hijiya
Abstract
A significantly higher incidence of SMN, especially hematological malignancies, was observed in this cohort compared to older neuroblastoma studies, potentially due to exposure to epipodophyllotoxins and a high cumulative dose of alkylating agents these patients received. The risk of developing an SMN continued to increase with survival time and did not reach the plateau at 15 years. Although the number of the patients is relatively small, our study emphasizes the need for life-long follow-up of survivors who were treated using modern therapy.
Related Papers
- → The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma(2006)88 cited
- → The Characteristics of Mediastinal Neuroblastoma(2000)40 cited
- → Low complex ganglioside expression characterizes human neuroblastoma cell lines(2005)38 cited
- Biological characteristics of N-myc amplified neuroblastoma in patients over one year of age.(1988)
- Current Clinical Trials in Neuroblastoma(2002)